Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Sclerosis | 120 | 2025 | 3250 | 9.190 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 34 | 2024 | 558 | 4.040 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 16 | 2024 | 256 | 2.200 |
Why?
|
Quality of Life | 27 | 2024 | 13510 | 1.460 |
Why?
|
Disability Evaluation | 29 | 2024 | 1839 | 1.420 |
Why?
|
Atrophy | 31 | 2024 | 1647 | 1.310 |
Why?
|
Immunologic Factors | 9 | 2024 | 1597 | 1.280 |
Why?
|
Disease Progression | 37 | 2024 | 13677 | 1.070 |
Why?
|
Magnetic Resonance Imaging | 76 | 2024 | 36861 | 1.070 |
Why?
|
Brain | 50 | 2024 | 27476 | 0.930 |
Why?
|
Neurofilament Proteins | 8 | 2023 | 337 | 0.910 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 3 | 2017 | 133 | 0.900 |
Why?
|
Severity of Illness Index | 32 | 2020 | 15955 | 0.870 |
Why?
|
Fatigue | 11 | 2021 | 1557 | 0.860 |
Why?
|
Spinal Cord | 11 | 2020 | 1813 | 0.790 |
Why?
|
Models, Statistical | 9 | 2015 | 5107 | 0.750 |
Why?
|
Amyotrophic Lateral Sclerosis | 4 | 2018 | 1473 | 0.750 |
Why?
|
Markov Chains | 5 | 2017 | 979 | 0.720 |
Why?
|
Interferon-beta | 4 | 2022 | 349 | 0.670 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2022 | 878 | 0.650 |
Why?
|
Cognitive Reserve | 2 | 2016 | 92 | 0.620 |
Why?
|
Demyelinating Diseases | 4 | 2016 | 358 | 0.600 |
Why?
|
MicroRNAs | 8 | 2023 | 3811 | 0.590 |
Why?
|
Adult | 128 | 2025 | 223818 | 0.550 |
Why?
|
Longitudinal Studies | 37 | 2025 | 14795 | 0.550 |
Why?
|
Image Interpretation, Computer-Assisted | 9 | 2019 | 3411 | 0.540 |
Why?
|
JC Virus | 2 | 2014 | 87 | 0.540 |
Why?
|
Mental Health | 7 | 2023 | 3275 | 0.540 |
Why?
|
Humans | 220 | 2025 | 768887 | 0.530 |
Why?
|
Immunosuppressive Agents | 12 | 2021 | 4207 | 0.530 |
Why?
|
Computers | 1 | 2018 | 592 | 0.520 |
Why?
|
Acute Coronary Syndrome | 9 | 2020 | 2194 | 0.520 |
Why?
|
Glial Fibrillary Acidic Protein | 5 | 2024 | 564 | 0.510 |
Why?
|
Female | 159 | 2025 | 397464 | 0.510 |
Why?
|
Bayes Theorem | 3 | 2015 | 2357 | 0.490 |
Why?
|
Male | 152 | 2025 | 365249 | 0.490 |
Why?
|
Middle Aged | 116 | 2025 | 223740 | 0.480 |
Why?
|
Health Behavior | 8 | 2021 | 2649 | 0.460 |
Why?
|
Cognition Disorders | 6 | 2020 | 3985 | 0.460 |
Why?
|
Nerve Fibers, Myelinated | 6 | 2012 | 953 | 0.450 |
Why?
|
Anxiety | 6 | 2024 | 4677 | 0.440 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2024 | 10397 | 0.440 |
Why?
|
Depression | 11 | 2020 | 8240 | 0.420 |
Why?
|
Social Stigma | 1 | 2020 | 788 | 0.420 |
Why?
|
Models, Genetic | 3 | 2008 | 3446 | 0.420 |
Why?
|
Monocytes | 3 | 2019 | 2603 | 0.410 |
Why?
|
Social Support | 4 | 2024 | 2193 | 0.400 |
Why?
|
Drug Resistance, Viral | 2 | 2008 | 869 | 0.400 |
Why?
|
Models, Psychological | 1 | 2016 | 826 | 0.400 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2010 | 330 | 0.380 |
Why?
|
Research Design | 5 | 2017 | 6213 | 0.370 |
Why?
|
Lymphocytes | 1 | 2019 | 2614 | 0.360 |
Why?
|
Optic Neuritis | 3 | 2021 | 175 | 0.360 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2010 | 640 | 0.350 |
Why?
|
Gadolinium | 4 | 2020 | 965 | 0.350 |
Why?
|
Blast Injuries | 2 | 2024 | 324 | 0.350 |
Why?
|
HIV | 2 | 2008 | 1596 | 0.340 |
Why?
|
Terminology as Topic | 2 | 2016 | 1541 | 0.330 |
Why?
|
Efficiency | 1 | 2012 | 480 | 0.330 |
Why?
|
Receptors, Interleukin-6 | 2 | 2020 | 224 | 0.320 |
Why?
|
Drug Substitution | 2 | 2017 | 291 | 0.320 |
Why?
|
HLA-B Antigens | 1 | 2010 | 328 | 0.320 |
Why?
|
Aniline Compounds | 2 | 2024 | 1094 | 0.310 |
Why?
|
Suicidal Ideation | 2 | 2016 | 1462 | 0.310 |
Why?
|
Models, Neurological | 1 | 2016 | 1783 | 0.300 |
Why?
|
Imaging, Three-Dimensional | 6 | 2018 | 4077 | 0.300 |
Why?
|
Parkinson Disease | 5 | 2023 | 2896 | 0.290 |
Why?
|
Administration, Intranasal | 3 | 2024 | 485 | 0.290 |
Why?
|
Military Personnel | 4 | 2024 | 1264 | 0.290 |
Why?
|
Patient Satisfaction | 3 | 2024 | 3489 | 0.280 |
Why?
|
Organ Size | 6 | 2017 | 2268 | 0.280 |
Why?
|
Disabled Persons | 3 | 2014 | 1210 | 0.280 |
Why?
|
Self Report | 3 | 2015 | 3773 | 0.270 |
Why?
|
Sample Size | 4 | 2017 | 848 | 0.270 |
Why?
|
Algorithms | 8 | 2021 | 14199 | 0.270 |
Why?
|
Exercise | 8 | 2022 | 5953 | 0.270 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2024 | 617 | 0.270 |
Why?
|
Neutrophils | 1 | 2019 | 3785 | 0.260 |
Why?
|
Adjuvants, Immunologic | 4 | 2022 | 999 | 0.250 |
Why?
|
Recurrence | 11 | 2024 | 8512 | 0.250 |
Why?
|
Neuropsychological Tests | 9 | 2025 | 7148 | 0.250 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2024 | 5716 | 0.240 |
Why?
|
Health Promotion | 7 | 2023 | 2210 | 0.240 |
Why?
|
Feasibility Studies | 13 | 2024 | 5323 | 0.240 |
Why?
|
Models, Theoretical | 2 | 2015 | 3580 | 0.230 |
Why?
|
Young Adult | 38 | 2024 | 60110 | 0.230 |
Why?
|
Probiotics | 2 | 2018 | 382 | 0.230 |
Why?
|
Disease | 1 | 2009 | 673 | 0.220 |
Why?
|
Encephalomyelitis, Acute Disseminated | 2 | 2015 | 68 | 0.220 |
Why?
|
Carrageenan | 1 | 2022 | 71 | 0.210 |
Why?
|
Amyloid beta-Peptides | 3 | 2024 | 3912 | 0.200 |
Why?
|
Dyspepsia | 1 | 2023 | 116 | 0.200 |
Why?
|
Cognition | 11 | 2024 | 7080 | 0.200 |
Why?
|
Age of Onset | 7 | 2022 | 3346 | 0.190 |
Why?
|
Autoantibodies | 2 | 2024 | 2126 | 0.190 |
Why?
|
Ferrous Compounds | 1 | 2001 | 41 | 0.190 |
Why?
|
Affect | 2 | 2019 | 1500 | 0.190 |
Why?
|
Fatty Acid-Binding Proteins | 2 | 2021 | 294 | 0.190 |
Why?
|
Herpesvirus 4, Human | 2 | 2024 | 1082 | 0.190 |
Why?
|
Upstream Stimulatory Factors | 1 | 2020 | 18 | 0.180 |
Why?
|
Spouse Abuse | 1 | 2022 | 182 | 0.180 |
Why?
|
Pilot Projects | 11 | 2024 | 8742 | 0.180 |
Why?
|
Positron-Emission Tomography | 4 | 2024 | 6673 | 0.180 |
Why?
|
Leptin | 3 | 2021 | 1597 | 0.180 |
Why?
|
Time Factors | 17 | 2020 | 40266 | 0.180 |
Why?
|
Integrative Medicine | 1 | 2022 | 87 | 0.180 |
Why?
|
Platelet Transfusion | 1 | 2023 | 301 | 0.180 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 9264 | 0.180 |
Why?
|
Thiazoles | 2 | 2024 | 1542 | 0.170 |
Why?
|
DNA, Viral | 1 | 2007 | 2205 | 0.170 |
Why?
|
Oxytocin | 1 | 2024 | 403 | 0.170 |
Why?
|
Antibodies, Viral | 5 | 2024 | 3216 | 0.170 |
Why?
|
Encephalomyelitis, Autoimmune, Experimental | 2 | 2022 | 822 | 0.170 |
Why?
|
Adipokines | 1 | 2021 | 309 | 0.160 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2024 | 667 | 0.160 |
Why?
|
Phylogeny | 1 | 2007 | 2843 | 0.160 |
Why?
|
Probability | 3 | 2023 | 2483 | 0.160 |
Why?
|
Computer Simulation | 5 | 2012 | 6289 | 0.160 |
Why?
|
Peptides | 6 | 2024 | 4353 | 0.160 |
Why?
|
Cohort Studies | 20 | 2023 | 41800 | 0.160 |
Why?
|
Peer Group | 1 | 2024 | 698 | 0.160 |
Why?
|
Retrospective Studies | 32 | 2024 | 81892 | 0.160 |
Why?
|
Adiponectin | 3 | 2021 | 1117 | 0.160 |
Why?
|
Speech Perception | 1 | 2023 | 512 | 0.160 |
Why?
|
Speech | 1 | 2023 | 558 | 0.160 |
Why?
|
Intermediate Filaments | 3 | 2023 | 171 | 0.160 |
Why?
|
Finite Element Analysis | 1 | 2001 | 442 | 0.150 |
Why?
|
Sex Characteristics | 3 | 2015 | 2660 | 0.150 |
Why?
|
Pattern Recognition, Automated | 3 | 2015 | 998 | 0.150 |
Why?
|
Evolution, Molecular | 1 | 2007 | 1894 | 0.150 |
Why?
|
Interferons | 1 | 2022 | 720 | 0.150 |
Why?
|
Superior Sagittal Sinus | 1 | 2017 | 15 | 0.150 |
Why?
|
Contrast Media | 2 | 2014 | 5334 | 0.150 |
Why?
|
Meninges | 1 | 2019 | 197 | 0.150 |
Why?
|
Prospective Studies | 17 | 2024 | 54950 | 0.150 |
Why?
|
Treatment Outcome | 18 | 2022 | 65485 | 0.150 |
Why?
|
Bifidobacterium | 1 | 2018 | 99 | 0.150 |
Why?
|
Th17 Cells | 2 | 2022 | 791 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2023 | 12252 | 0.140 |
Why?
|
Subtraction Technique | 2 | 2011 | 519 | 0.140 |
Why?
|
Psychotherapy | 2 | 2019 | 1654 | 0.140 |
Why?
|
Risk | 4 | 2019 | 9621 | 0.140 |
Why?
|
Logistic Models | 7 | 2020 | 13317 | 0.140 |
Why?
|
Teaching Rounds | 1 | 2021 | 282 | 0.140 |
Why?
|
Wine | 1 | 2017 | 172 | 0.140 |
Why?
|
Vision Tests | 1 | 2017 | 160 | 0.130 |
Why?
|
Blood Transfusion | 1 | 2023 | 1309 | 0.130 |
Why?
|
Optic Nerve | 1 | 2020 | 571 | 0.130 |
Why?
|
Radiometry | 2 | 2003 | 817 | 0.130 |
Why?
|
Aged | 32 | 2024 | 171790 | 0.130 |
Why?
|
Cerebral Cortex | 3 | 2018 | 5834 | 0.130 |
Why?
|
Folic Acid | 1 | 2023 | 1336 | 0.130 |
Why?
|
Postmenopause | 2 | 2015 | 2519 | 0.130 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1907 | 0.130 |
Why?
|
Sickness Impact Profile | 2 | 2015 | 299 | 0.130 |
Why?
|
Cross-Sectional Studies | 14 | 2025 | 26384 | 0.130 |
Why?
|
Psychotherapy, Group | 1 | 2019 | 417 | 0.120 |
Why?
|
Smoking | 3 | 2023 | 9094 | 0.120 |
Why?
|
Lower Extremity | 1 | 2023 | 1217 | 0.120 |
Why?
|
Computers, Handheld | 1 | 2017 | 211 | 0.120 |
Why?
|
Alzheimer Disease | 4 | 2024 | 8758 | 0.120 |
Why?
|
HLA Antigens | 2 | 2010 | 1336 | 0.120 |
Why?
|
Personal Satisfaction | 1 | 2019 | 645 | 0.120 |
Why?
|
Early Diagnosis | 1 | 2020 | 1195 | 0.120 |
Why?
|
Injections | 1 | 2017 | 841 | 0.120 |
Why?
|
Predictive Value of Tests | 9 | 2015 | 15471 | 0.110 |
Why?
|
Propylene Glycols | 1 | 2014 | 91 | 0.110 |
Why?
|
Sensitivity and Specificity | 11 | 2017 | 14751 | 0.110 |
Why?
|
Vaccines | 1 | 2022 | 842 | 0.110 |
Why?
|
Abortion, Spontaneous | 1 | 2018 | 534 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 4 | 2013 | 18065 | 0.110 |
Why?
|
Heart Diseases | 3 | 2016 | 2819 | 0.110 |
Why?
|
Statistics, Nonparametric | 4 | 2017 | 2862 | 0.110 |
Why?
|
Medical Informatics | 1 | 2020 | 742 | 0.110 |
Why?
|
Adolescent | 23 | 2023 | 89247 | 0.110 |
Why?
|
Neurology | 1 | 2021 | 787 | 0.110 |
Why?
|
Reproducibility of Results | 9 | 2017 | 20244 | 0.110 |
Why?
|
Incidence | 8 | 2024 | 21545 | 0.110 |
Why?
|
Body Mass Index | 6 | 2021 | 13054 | 0.100 |
Why?
|
Calibration | 1 | 2015 | 823 | 0.100 |
Why?
|
Prognosis | 10 | 2020 | 30044 | 0.100 |
Why?
|
Uveal Neoplasms | 1 | 2016 | 344 | 0.100 |
Why?
|
Aging | 4 | 2021 | 8765 | 0.100 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 1002 | 0.100 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 257 | 0.100 |
Why?
|
Models, Biological | 1 | 2009 | 9499 | 0.100 |
Why?
|
Behavior Therapy | 1 | 2018 | 886 | 0.100 |
Why?
|
Databases, Factual | 4 | 2019 | 8095 | 0.100 |
Why?
|
HLA-DR Antigens | 2 | 2010 | 609 | 0.100 |
Why?
|
Image Enhancement | 5 | 2020 | 2898 | 0.100 |
Why?
|
Serologic Tests | 1 | 2014 | 383 | 0.100 |
Why?
|
Sphingosine | 1 | 2014 | 308 | 0.100 |
Why?
|
Visual Acuity | 3 | 2021 | 2714 | 0.100 |
Why?
|
Inflammation Mediators | 1 | 2020 | 1890 | 0.100 |
Why?
|
Heart Failure | 4 | 2021 | 11879 | 0.100 |
Why?
|
Osteopontin | 1 | 2013 | 311 | 0.100 |
Why?
|
Inflammation | 3 | 2019 | 10869 | 0.090 |
Why?
|
Data Interpretation, Statistical | 3 | 2013 | 2714 | 0.090 |
Why?
|
Neuromyelitis Optica | 1 | 2015 | 266 | 0.090 |
Why?
|
Postpartum Period | 1 | 2018 | 1198 | 0.090 |
Why?
|
Cervical Vertebrae | 2 | 2015 | 982 | 0.090 |
Why?
|
Absenteeism | 1 | 2012 | 247 | 0.090 |
Why?
|
Regression Analysis | 3 | 2011 | 6346 | 0.090 |
Why?
|
Random Allocation | 1 | 2015 | 2396 | 0.090 |
Why?
|
Boston | 4 | 2020 | 9375 | 0.090 |
Why?
|
Follow-Up Studies | 12 | 2023 | 39394 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2747 | 0.090 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 2260 | 0.090 |
Why?
|
Receptor, Adenosine A1 | 1 | 2010 | 42 | 0.090 |
Why?
|
Panic Disorder | 1 | 2014 | 613 | 0.090 |
Why?
|
Food Hypersensitivity | 1 | 2018 | 734 | 0.090 |
Why?
|
Patient Compliance | 2 | 2019 | 2701 | 0.090 |
Why?
|
Inpatients | 2 | 2013 | 2570 | 0.090 |
Why?
|
Models, Economic | 2 | 2016 | 721 | 0.090 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2022 | 4651 | 0.090 |
Why?
|
HLA-C Antigens | 1 | 2010 | 146 | 0.090 |
Why?
|
Plasma | 2 | 2020 | 585 | 0.090 |
Why?
|
HLA-A Antigens | 1 | 2010 | 223 | 0.090 |
Why?
|
Receptor, Adenosine A2A | 1 | 2010 | 129 | 0.090 |
Why?
|
Health Care Costs | 2 | 2016 | 3270 | 0.090 |
Why?
|
Phenotype | 5 | 2020 | 16735 | 0.080 |
Why?
|
Likelihood Functions | 2 | 2016 | 993 | 0.080 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2010 | 165 | 0.080 |
Why?
|
Vision Disorders | 1 | 2017 | 1093 | 0.080 |
Why?
|
Probability Theory | 1 | 2009 | 11 | 0.080 |
Why?
|
Levodopa | 1 | 2010 | 223 | 0.080 |
Why?
|
Cytokines | 3 | 2020 | 7453 | 0.080 |
Why?
|
Antiparkinson Agents | 1 | 2010 | 184 | 0.080 |
Why?
|
Epidemiologic Research Design | 1 | 2013 | 368 | 0.080 |
Why?
|
Cell Migration Inhibition | 1 | 2009 | 97 | 0.080 |
Why?
|
Albuterol | 1 | 2010 | 211 | 0.080 |
Why?
|
HIV-1 | 1 | 2007 | 6963 | 0.080 |
Why?
|
Administration, Oral | 1 | 2017 | 4042 | 0.080 |
Why?
|
Personality | 1 | 2013 | 560 | 0.080 |
Why?
|
tau Proteins | 3 | 2024 | 2145 | 0.080 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2009 | 139 | 0.080 |
Why?
|
Leukoencephalopathies | 1 | 2012 | 260 | 0.080 |
Why?
|
Pyrroles | 1 | 2015 | 1126 | 0.080 |
Why?
|
Reference Values | 3 | 2011 | 4941 | 0.080 |
Why?
|
Obesity | 3 | 2024 | 13087 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 2422 | 0.080 |
Why?
|
Employment | 1 | 2015 | 1114 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2019 | 3518 | 0.080 |
Why?
|
Attitude | 1 | 2013 | 772 | 0.080 |
Why?
|
Infant Food | 1 | 2009 | 139 | 0.080 |
Why?
|
Thalamus | 2 | 2018 | 1050 | 0.080 |
Why?
|
Resilience, Psychological | 1 | 2016 | 808 | 0.080 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2022 | 3116 | 0.080 |
Why?
|
Walking | 3 | 2013 | 1201 | 0.080 |
Why?
|
Normal Distribution | 1 | 2009 | 272 | 0.080 |
Why?
|
Feeding Behavior | 1 | 2020 | 3206 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 7 | 2024 | 9081 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1060 | 0.070 |
Why?
|
Androgens | 1 | 2015 | 1285 | 0.070 |
Why?
|
Health Status Indicators | 1 | 2013 | 971 | 0.070 |
Why?
|
Insulin Resistance | 2 | 2020 | 3982 | 0.070 |
Why?
|
Patient Care | 1 | 2013 | 629 | 0.070 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 306 | 0.070 |
Why?
|
Sex Distribution | 2 | 2011 | 2280 | 0.070 |
Why?
|
Poisson Distribution | 1 | 2009 | 508 | 0.070 |
Why?
|
Captopril | 1 | 1988 | 262 | 0.070 |
Why?
|
Endpoint Determination | 1 | 2010 | 594 | 0.070 |
Why?
|
Infant Formula | 1 | 2009 | 195 | 0.070 |
Why?
|
Brain Infarction | 1 | 2009 | 288 | 0.070 |
Why?
|
HIV Reverse Transcriptase | 1 | 2008 | 214 | 0.070 |
Why?
|
Chi-Square Distribution | 2 | 2010 | 3438 | 0.070 |
Why?
|
Suicide, Attempted | 1 | 2016 | 1409 | 0.070 |
Why?
|
Enterobacteriaceae Infections | 1 | 2009 | 190 | 0.070 |
Why?
|
Medulla Oblongata | 1 | 2008 | 248 | 0.070 |
Why?
|
Interferon Type I | 1 | 2011 | 569 | 0.070 |
Why?
|
Genes, Viral | 1 | 2008 | 655 | 0.070 |
Why?
|
Gene Frequency | 2 | 2010 | 3625 | 0.070 |
Why?
|
Risk Factors | 9 | 2023 | 74971 | 0.070 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2006 | 52 | 0.070 |
Why?
|
Prevalence | 5 | 2022 | 15875 | 0.070 |
Why?
|
Pregnancy Complications | 1 | 2020 | 2965 | 0.070 |
Why?
|
Age Distribution | 2 | 2009 | 2875 | 0.070 |
Why?
|
Prothrombin Time | 1 | 2006 | 117 | 0.070 |
Why?
|
Attitude to Health | 1 | 2015 | 2025 | 0.070 |
Why?
|
Basal Ganglia | 1 | 2009 | 555 | 0.070 |
Why?
|
Clinical Trials as Topic | 3 | 2014 | 8055 | 0.070 |
Why?
|
Testosterone | 2 | 2014 | 2494 | 0.070 |
Why?
|
Child | 13 | 2024 | 80969 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 3 | 2014 | 6546 | 0.070 |
Why?
|
Age Factors | 7 | 2020 | 18454 | 0.070 |
Why?
|
Cerebrospinal Fluid | 1 | 2009 | 545 | 0.060 |
Why?
|
Double-Blind Method | 4 | 2024 | 12469 | 0.060 |
Why?
|
New England | 1 | 2009 | 1058 | 0.060 |
Why?
|
Artifacts | 1 | 2014 | 1942 | 0.060 |
Why?
|
Biometry | 1 | 2009 | 570 | 0.060 |
Why?
|
Linear Models | 4 | 2017 | 5890 | 0.060 |
Why?
|
Recovery of Function | 2 | 2014 | 2990 | 0.060 |
Why?
|
Blood Component Transfusion | 1 | 2006 | 141 | 0.060 |
Why?
|
Comorbidity | 1 | 2020 | 10591 | 0.060 |
Why?
|
Splenectomy | 1 | 2007 | 392 | 0.060 |
Why?
|
Health Services Needs and Demand | 1 | 2013 | 1407 | 0.060 |
Why?
|
Telephone | 2 | 2020 | 630 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 3233 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 3780 | 0.060 |
Why?
|
Emotions | 1 | 2017 | 2768 | 0.060 |
Why?
|
Corpus Callosum | 1 | 2009 | 754 | 0.060 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2008 | 622 | 0.060 |
Why?
|
Patient Care Team | 1 | 2016 | 2527 | 0.060 |
Why?
|
Platelet Count | 2 | 2023 | 787 | 0.060 |
Why?
|
Diffusion Tensor Imaging | 2 | 2012 | 2426 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2019 | 3200 | 0.060 |
Why?
|
Seasons | 1 | 2010 | 1523 | 0.060 |
Why?
|
Alcohol Drinking | 1 | 2017 | 4045 | 0.060 |
Why?
|
HIV Protease Inhibitors | 1 | 2006 | 432 | 0.060 |
Why?
|
Genome, Viral | 1 | 2008 | 673 | 0.060 |
Why?
|
Proportional Hazards Models | 3 | 2016 | 12563 | 0.060 |
Why?
|
Survival Analysis | 2 | 2015 | 10115 | 0.050 |
Why?
|
Gait | 1 | 2009 | 822 | 0.050 |
Why?
|
Aged, 80 and over | 6 | 2024 | 59738 | 0.050 |
Why?
|
Iron | 2 | 2009 | 1813 | 0.050 |
Why?
|
Beverages | 1 | 2009 | 819 | 0.050 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2024 | 158 | 0.050 |
Why?
|
Memory | 1 | 2013 | 2210 | 0.050 |
Why?
|
Renin-Angiotensin System | 1 | 1988 | 736 | 0.050 |
Why?
|
HIV Infections | 2 | 2008 | 17589 | 0.050 |
Why?
|
Explosions | 1 | 2023 | 107 | 0.050 |
Why?
|
Mental Disorders | 2 | 2013 | 6879 | 0.050 |
Why?
|
Depressive Disorder | 2 | 2013 | 3726 | 0.050 |
Why?
|
Blood Coagulation Disorders | 1 | 2006 | 350 | 0.050 |
Why?
|
Survivors | 2 | 2024 | 2383 | 0.050 |
Why?
|
Case-Control Studies | 5 | 2024 | 22294 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 2019 | 4300 | 0.050 |
Why?
|
Muromonab-CD3 | 1 | 2022 | 104 | 0.050 |
Why?
|
Nasal Sprays | 1 | 2022 | 27 | 0.050 |
Why?
|
Software | 2 | 2015 | 4480 | 0.050 |
Why?
|
Pancreatectomy | 1 | 2007 | 825 | 0.050 |
Why?
|
Lymphocyte Depletion | 1 | 2024 | 605 | 0.050 |
Why?
|
Genotype | 3 | 2013 | 13048 | 0.050 |
Why?
|
Vitamin B 6 | 1 | 2023 | 237 | 0.050 |
Why?
|
Mycophenolic Acid | 1 | 2024 | 348 | 0.050 |
Why?
|
Cost-Benefit Analysis | 2 | 2016 | 5544 | 0.050 |
Why?
|
Antigens, CD20 | 1 | 2022 | 199 | 0.050 |
Why?
|
rho-Associated Kinases | 1 | 2023 | 285 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5892 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2011 | 6512 | 0.050 |
Why?
|
Arrhythmias, Cardiac | 1 | 2011 | 2258 | 0.050 |
Why?
|
Spleen | 1 | 2007 | 2294 | 0.050 |
Why?
|
Internet | 1 | 2013 | 3112 | 0.040 |
Why?
|
Immunoconjugates | 1 | 2008 | 976 | 0.040 |
Why?
|
Research Subjects | 1 | 2022 | 249 | 0.040 |
Why?
|
Receptors, CCR6 | 1 | 2020 | 73 | 0.040 |
Why?
|
Neocortex | 1 | 2024 | 417 | 0.040 |
Why?
|
Spinal Cord Injuries | 1 | 2008 | 929 | 0.040 |
Why?
|
Sucrose | 1 | 2001 | 158 | 0.040 |
Why?
|
Analysis of Variance | 3 | 2014 | 6242 | 0.040 |
Why?
|
Sodium Chloride | 1 | 2022 | 584 | 0.040 |
Why?
|
Intubation | 1 | 2020 | 140 | 0.040 |
Why?
|
Solutions | 1 | 2001 | 410 | 0.040 |
Why?
|
British Columbia | 1 | 2020 | 240 | 0.040 |
Why?
|
Body Composition | 2 | 2024 | 2461 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2020 | 125 | 0.040 |
Why?
|
Vitamin B 12 | 1 | 2023 | 528 | 0.040 |
Why?
|
Gels | 1 | 2001 | 422 | 0.040 |
Why?
|
Vaccination | 2 | 2022 | 3436 | 0.040 |
Why?
|
Pharynx | 1 | 2022 | 436 | 0.040 |
Why?
|
Coronary Artery Disease | 2 | 2019 | 6569 | 0.040 |
Why?
|
Receptors, CXCR3 | 1 | 2020 | 240 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2016 | 15662 | 0.040 |
Why?
|
Chelating Agents | 1 | 2001 | 385 | 0.040 |
Why?
|
Radiography | 1 | 2010 | 6991 | 0.040 |
Why?
|
REM Sleep Behavior Disorder | 1 | 2020 | 111 | 0.040 |
Why?
|
Abortion, Therapeutic | 1 | 2018 | 35 | 0.040 |
Why?
|
Prednisone | 1 | 2024 | 1567 | 0.040 |
Why?
|
Patient Readmission | 1 | 2013 | 3313 | 0.040 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2023 | 642 | 0.040 |
Why?
|
Diffusion | 1 | 2001 | 818 | 0.040 |
Why?
|
Auditory Perception | 1 | 2023 | 588 | 0.040 |
Why?
|
T-Lymphocytes | 2 | 2023 | 10276 | 0.040 |
Why?
|
Adaptation, Psychological | 1 | 2009 | 2667 | 0.040 |
Why?
|
Antidepressive Agents | 1 | 2011 | 2914 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11886 | 0.040 |
Why?
|
GTP-Binding Proteins | 1 | 2023 | 947 | 0.040 |
Why?
|
Carnitine | 1 | 2020 | 253 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2007 | 4123 | 0.040 |
Why?
|
Sex Factors | 3 | 2019 | 10641 | 0.040 |
Why?
|
Ownership | 1 | 2020 | 344 | 0.040 |
Why?
|
Puerperal Disorders | 1 | 2020 | 303 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2022 | 753 | 0.040 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2009 | 2831 | 0.040 |
Why?
|
Leukopenia | 1 | 2017 | 212 | 0.040 |
Why?
|
Melanoma | 1 | 2016 | 5709 | 0.040 |
Why?
|
Biological Assay | 1 | 2020 | 628 | 0.040 |
Why?
|
Th1 Cells | 1 | 2022 | 1042 | 0.030 |
Why?
|
Lactobacillus | 1 | 2018 | 212 | 0.030 |
Why?
|
Neurons | 2 | 2022 | 9524 | 0.030 |
Why?
|
United States | 6 | 2024 | 73180 | 0.030 |
Why?
|
Temporal Lobe | 1 | 2024 | 1728 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2009 | 4568 | 0.030 |
Why?
|
Genome-Wide Association Study | 2 | 2020 | 12798 | 0.030 |
Why?
|
Eating | 1 | 2023 | 1542 | 0.030 |
Why?
|
Mutation | 2 | 2013 | 30266 | 0.030 |
Why?
|
Energy Intake | 1 | 2024 | 2146 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3814 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2020 | 4356 | 0.030 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2003 | 1232 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2007 | 4784 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4862 | 0.030 |
Why?
|
Constipation | 1 | 2020 | 570 | 0.030 |
Why?
|
Endothelin-1 | 1 | 2017 | 296 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2017 | 793 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2024 | 4835 | 0.030 |
Why?
|
Genetic Variation | 2 | 2009 | 6610 | 0.030 |
Why?
|
Lymphopenia | 1 | 2017 | 299 | 0.030 |
Why?
|
Demyelinating Autoimmune Diseases, CNS | 1 | 2015 | 40 | 0.030 |
Why?
|
Injections, Intramuscular | 1 | 2016 | 556 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2019 | 620 | 0.030 |
Why?
|
Signal Transduction | 3 | 2020 | 23652 | 0.030 |
Why?
|
Aquaporin 4 | 1 | 2015 | 161 | 0.030 |
Why?
|
Pregnancy Trimester, First | 1 | 2018 | 917 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2003 | 1679 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2663 | 0.030 |
Why?
|
Hemorrhage | 1 | 2006 | 3465 | 0.030 |
Why?
|
Autoimmunity | 1 | 2022 | 1360 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2018 | 1048 | 0.030 |
Why?
|
Online Systems | 1 | 2014 | 182 | 0.030 |
Why?
|
Phorbol Esters | 1 | 2013 | 109 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2017 | 1609 | 0.030 |
Why?
|
Neurotic Disorders | 1 | 2013 | 77 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 4413 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2017 | 1133 | 0.030 |
Why?
|
Steroids | 1 | 2018 | 938 | 0.030 |
Why?
|
Pregnancy | 3 | 2020 | 30175 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2024 | 2905 | 0.030 |
Why?
|
Mice | 4 | 2023 | 82074 | 0.030 |
Why?
|
Blood Platelets | 1 | 2023 | 2479 | 0.030 |
Why?
|
Weight Loss | 1 | 2024 | 2720 | 0.030 |
Why?
|
Chemokine CXCL10 | 1 | 2013 | 312 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2001 | 2533 | 0.020 |
Why?
|
Gene Expression Regulation | 3 | 2018 | 11934 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2008 | 4576 | 0.020 |
Why?
|
Health Surveys | 2 | 2013 | 4055 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 3433 | 0.020 |
Why?
|
Nurses | 1 | 2021 | 2501 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2018 | 1855 | 0.020 |
Why?
|
Interferon-gamma | 2 | 2010 | 3163 | 0.020 |
Why?
|
Interleukin-17 | 1 | 2017 | 925 | 0.020 |
Why?
|
Purinergic P1 Receptor Antagonists | 1 | 2010 | 45 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1381 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2024 | 4794 | 0.020 |
Why?
|
Critical Care | 1 | 2023 | 2715 | 0.020 |
Why?
|
SEER Program | 1 | 2016 | 1473 | 0.020 |
Why?
|
Glutamine | 1 | 2013 | 578 | 0.020 |
Why?
|
Cost Savings | 1 | 2016 | 915 | 0.020 |
Why?
|
Oxidopamine | 1 | 2010 | 173 | 0.020 |
Why?
|
Enkephalins | 1 | 2010 | 139 | 0.020 |
Why?
|
Adrenergic Agents | 1 | 2010 | 73 | 0.020 |
Why?
|
Dynorphins | 1 | 2010 | 82 | 0.020 |
Why?
|
Metabolomics | 1 | 2020 | 1675 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 937 | 0.020 |
Why?
|
Personality Inventory | 1 | 2013 | 1018 | 0.020 |
Why?
|
Verbal Behavior | 1 | 2011 | 336 | 0.020 |
Why?
|
Child, Preschool | 4 | 2016 | 42684 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2784 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2023 | 3442 | 0.020 |
Why?
|
Health Status | 2 | 2016 | 4095 | 0.020 |
Why?
|
Animals | 5 | 2023 | 169408 | 0.020 |
Why?
|
Vitamin D | 2 | 2014 | 3311 | 0.020 |
Why?
|
Arginine | 1 | 2013 | 932 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3069 | 0.020 |
Why?
|
Odds Ratio | 2 | 2013 | 9682 | 0.020 |
Why?
|
Health Resources | 1 | 2016 | 951 | 0.020 |
Why?
|
Interferon Regulatory Factors | 1 | 2010 | 271 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 1741 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2017 | 12809 | 0.020 |
Why?
|
Adrenergic beta-Agonists | 1 | 2010 | 347 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2022 | 22381 | 0.020 |
Why?
|
Anisotropy | 1 | 2012 | 1295 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2016 | 1515 | 0.020 |
Why?
|
Qualitative Research | 1 | 2020 | 3143 | 0.020 |
Why?
|
Angiotensin I | 1 | 1988 | 48 | 0.020 |
Why?
|
Consumer Product Safety | 1 | 2009 | 122 | 0.020 |
Why?
|
Brain Mapping | 1 | 2023 | 6740 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2017 | 1751 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2730 | 0.020 |
Why?
|
Health Personnel | 1 | 2022 | 3382 | 0.020 |
Why?
|
Interleukin-13 | 1 | 2010 | 391 | 0.020 |
Why?
|
Demography | 1 | 2013 | 1643 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4755 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7602 | 0.020 |
Why?
|
Movement Disorders | 1 | 2011 | 464 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2011 | 1585 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2017 | 6031 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2008 | 0.020 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2009 | 660 | 0.020 |
Why?
|
Protein Precursors | 1 | 2010 | 1135 | 0.020 |
Why?
|
Estrogens | 1 | 2013 | 1537 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2023 | 7885 | 0.020 |
Why?
|
Syndrome | 1 | 2012 | 3274 | 0.020 |
Why?
|
Caffeine | 1 | 2010 | 703 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12873 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9442 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2013 | 1942 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7245 | 0.020 |
Why?
|
Pancreatic Diseases | 1 | 2007 | 353 | 0.010 |
Why?
|
Overweight | 1 | 2016 | 2445 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2009 | 1616 | 0.010 |
Why?
|
Drug Resistance | 1 | 2010 | 1600 | 0.010 |
Why?
|
Cardiovascular Agents | 1 | 2011 | 849 | 0.010 |
Why?
|
Memory, Short-Term | 1 | 2011 | 1010 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2015 | 5905 | 0.010 |
Why?
|
Area Under Curve | 1 | 2009 | 1645 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9549 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2022 | 11684 | 0.010 |
Why?
|
Thoracic Vertebrae | 1 | 2009 | 614 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2003 | 5434 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2017 | 5150 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2013 | 4291 | 0.010 |
Why?
|
Corpus Striatum | 1 | 2010 | 1237 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2014 | 6856 | 0.010 |
Why?
|
Coronary Angiography | 1 | 2015 | 4541 | 0.010 |
Why?
|
Psychometrics | 1 | 2013 | 3066 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2013 | 2122 | 0.010 |
Why?
|
Adiposity | 1 | 2013 | 1895 | 0.010 |
Why?
|
Immune System | 1 | 2008 | 800 | 0.010 |
Why?
|
Myocardial Contraction | 1 | 1988 | 1526 | 0.010 |
Why?
|
Sodium | 1 | 1988 | 1597 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2009 | 1476 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2009 | 1895 | 0.010 |
Why?
|
Europe | 1 | 2009 | 3441 | 0.010 |
Why?
|
Homeostasis | 1 | 2013 | 3348 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2013 | 3335 | 0.010 |
Why?
|
Creatinine | 1 | 2006 | 1917 | 0.010 |
Why?
|
Infant | 2 | 2016 | 36541 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 6320 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6901 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7860 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12093 | 0.010 |
Why?
|
Insulin | 1 | 2013 | 6610 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2009 | 5505 | 0.010 |
Why?
|
Massachusetts | 1 | 2011 | 8888 | 0.010 |
Why?
|
Hemodynamics | 1 | 1988 | 4199 | 0.010 |
Why?
|
Registries | 1 | 2013 | 8384 | 0.010 |
Why?
|
Telemedicine | 1 | 2014 | 3109 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 10778 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2003 | 2920 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2016 | 7956 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2010 | 14485 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 24330 | 0.010 |
Why?
|
Hospitalization | 1 | 2013 | 10845 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2009 | 19023 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2010 | 18366 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2009 | 26394 | 0.000 |
Why?
|
Postoperative Complications | 1 | 2007 | 15889 | 0.000 |
Why?
|
Lung Neoplasms | 1 | 2003 | 13593 | 0.000 |
Why?
|